Court blocks Edwards Lifesciences' JenaValve acquisition

A U.S. District Court granted the Federal Trade Commission's motion for an injunction blocking Edwards Lifesciences Corporation's (NYSE: EW) proposed acquisition of JenaValve Technology, the company announced.

The ruling prevents Edwards from completing the transaction. Edwards stated it disagrees with the decision and believes the acquisition would have benefited patients with aortic regurgitation, a condition the company describes as under-detected and carrying high mortality rates when untreated.

Edwards said it remains committed to developing treatments for aortic regurgitation and will continue advancing its SOJOURN transcatheter valve and enrolling patients in the JOURNEY pivotal trial.

The company revised its full-year 2026 adjusted earnings per share guidance to $2.90-$3.05, up from previous guidance of $2.80-$2.95. Edwards said the revision reflects the impact of not proceeding with the JenaValve acquisition.

The adjusted earnings per share excludes litigation expenses, amortization of intangible assets, impairment losses and separation costs. Edwards plans to provide additional updates during its fourth quarter earnings call in February.

You May Also Be Interested In

• Arcosa stockholders approve $150-per-share cash buyout by CRH
• USA Rare Earth completes merger with Serra Verde Group
• EU proposes to curb Airbnb and short-term rentals amid housing shortage